PKD - Safety Committee Approves Dose Escalation
Filed with ASX · · 4 pages · English
PYC Therapeutics Limited on 6ix
In the deck
Earlier from PYC Therapeutics
- ADOA Program Update
- PKD - Initiation of Multiple Dose Clinical Trial
- Presentation of Ophthalmology Clinical Trial Data at ARVO
- ADOA Program - SRC Approve Progression to Multi-Dose Study
- Completion of Retail Entitlement Offer
Later from PYC Therapeutics
- S&P DJI Announces September 2026 Quarterly Rebalance
- PKD Program - Presentation of Data at ASN Conference
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics